Zai Lab finds lat­est tar­get in Re­gen­eron’s bis­pe­cif­ic, pay­ing up to $190M for Chi­nese rights

Nine months af­ter hint­ing they might have bis­pe­cif­ic an­ti­bod­ies in the works, Shang­hai-based Zai Lab has signed on to help com­mer­cial­ize one of biotech’s most …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER